Nexstim Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Nexstim (HEL:NXTMH) Full Year 2024 Results

Key Financial Results

• Revenue: €10.2m (up 19% from FY 2023).
• Net loss: €892.3k (loss narrowed by 33% from FY 2023).
• €0.13 loss per share (improved from €0.20 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nexstim Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates.

In the last 12 months, the only revenue segment was Surgical & Medical Equipment contributing €10.2m. The largest operating expense was General & Administrative costs, amounting to €4.78m (52% of total expenses). Explore how NXTMH's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are down 18% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Nexstim has 2 warning signs (and 1 which is significant) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.